Floatz logo

Trastuzumab Rezetecan

Trastuzumab-rezetecan

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universityantibody_drug_conjugateActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Trastuzumab-rezetecan cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Trastuzumab Rezetecan is also rated in:

breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →
HER2 positive breast carcinomaDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →